Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent ( Abbott's Bioabsorbable Stent Technology...)

HOME >> MEDICINE >> TECHNOLOGY

Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Patients with Coronary Artery Disease

ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Abbott today announced positive results from ABSORB, the world's first clinical trial evaluating the overall safety and performance of a fully bioabsorbable drug- eluting stent platform for the treatment of coronary artery disease. Six- month results from the first 30 patients in the trial, presented at the 56th Annual of Cardiology Scientific Session in New Orleans, demonstrated no stent thrombosis and a low (3.3 percent) hierarchical rate of ischemia-driven Major Adverse Cardiac Events (MACE), such as heart attack or repeat intervention.

"The encouraging results from the first 30 patients of ABSORB suggest that drug-eluting bioabsorbable stent technologies may be a promising future therapy option for physicians treating patients with heart disease," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, who is co-principal investigator of the study. "A drug eluting stent that would eventually disappear after restoring blood flow is an exciting concept that we look forward to further exploring."

The single MACE event reported was a non-Q-wave myocardial infarction. The same patient underwent a repeat intervention that occurred at the site of the original procedure, resulting in an overall target lesion revascularization rate of 3.3 percent. The trial results confirmed that the treatment effect of everolimus in the bioabsorbable stent is similar to that observed in Abbott's studies of metallic drug-eluting stents, with everolimus actively inhibiting tissue growth into the artery. The rate of device success (successful placement of the bioabsorbable stent at the site of the lesion) was 93.5 percent.

'"/>

Page: 1 2 3
Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:

(Date:6/17/2013)... June 17, 2013 Today BioSpace , the leading ... BioCapital Hotbed map campaign spotlighting the life sciences community ... , Delaware and Washington ... ) The BioCapital area continues to ... BioSpace.com average 21 applies each - a strong ...

(Date:6/17/2013)... , June 17, 2013 Actavis, Inc. (NYSE: ... Court has reversed the decision of the U.S. Court of ... Court,s ruling granting Actavis, motion to dismiss the Federal Trade ... Court,s reversal was the result of a decision by a ... "quick look" approach and adopted the traditional "rule of reason" ...

(Date:6/17/2013)... June 17, 2013 Royal Philips (NYSE: ... for its Iterative Model Reconstruction (IMR) technology, ... simultaneously bring enhanced benefits to clinicians and ... the International Society for Computed Tomography,s (ISCT) ... and include IMR,s ability to simultaneously deliver ...

Breaking Medicine Technology:Mid-Atlantic Biotech Leaders Featured On BioSpace Map 2 U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 2 U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 3 Philips IMR offers new capabilities to simultaneously reduce CT Radiation and enhance image quality 2 Philips IMR offers new capabilities to simultaneously reduce CT Radiation and enhance image quality 3

[0] Mid-Atlantic Biotech Leaders Featured On BioSpace Map [0] U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis [0] Philips IMR offers new capabilities to simultaneously reduce CT Radiation and enhance image quality

... MORRISTOWN, N.J., Jan. 3, 2012 Actavis Group, ... it has begun shipping Clobetasol Propionate Shampoo and ... ® Shampoo and Clobex ® Topical ... has granted Actavis a 180-day marketing exclusivity. ...

... Jan. 3, 2012 Cyberonics, Inc. (NASDAQ: CYBX ) ... (FDA) has approved its re-designed AspireHC (High Capacity) generator, which ... 2011. "We are pleased that the FDA was ... us to resume our limited commercial release of the AspireHC ...

Cached Medicine Technology:Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion 2 Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy 2 Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy 3

Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy

(Date:6/17/2013)... New York (PRWEB) June 18, 2013 ... has more physicians listed in New York magazine's ... In the latest survey, 209 NewYork-Presbyterian physicians from ... fortunate to have some of the nation's best ... J. Corwin, CEO of NewYork-Presbyterian Hospital. "We are ...

(Date:6/17/2013)... and Drug Administration (FDA) imposes new graphic warning ... First Amendment challenge if they depict health consequences ... evidence, says a Georgetown University Medical Center public ... warning labelswhich combine images with health warningsare a ... other countries, but the tobacco industry argues they ...

(Date:6/17/2013)... MA (PRWEB) June 17, 2013 Daimer ... robust steam cleaner equipment , such as expertly designed ... launched the KleenJet® Pro Plus 200S for apartment dwellers ... up to 310°F in 15 minutes and pressure levels ... effectively. The machine can be used to clean carpet ...

(Date:6/17/2013)... Bust’DD (pronounced ‘busted’), a new company that ... women with large busts, will soon launch their crowdfunding campaign ... understand the problem of ill-fitting bras and want to offer ... is to raise at least $25,000 to create their beta ... on a wide scale. , In order to kick off ...

(Date:6/17/2013)... (PRWEB) June 17, 2013 Today, ... stand-alone HRAs for small businesses . Zane Benefits, ... employer sponsored health benefits, is the leader in ... arrangements . , According to Zane Benefits’ website, ... Accounts or HRAs, offer small businesses an affordable ...

Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List 2 Health News:Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge? 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 3 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3 Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2

[0] NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List [0] Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?[0] Daimer Ships Vapor Steam Cleaner For Homeowners [0] Arizona Startup Bust’DD Looking to Start a BRAvolution [0] Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses

... , , , ... , the global leader in thin computing and client virtualization, today announced ... Smiles is a rapidly-growing company whose mission is to bring quality dental ... first office in 2002 in Atlanta, GA, the network has demonstrated substantial ...

... , , , ... Health, Inc. (Nasdaq: GHDX ) today announced that Kim ... Adams 29th Annual Global Growth Conference in Boston, on Thursday, August ... access the live and subsequently archived webcast of the presentation, visit ...

... , , , ... Aug. 6 CSC (NYSE: CSC ... company as a preferred provider to help member hospitals comply with the ... U.S. federal government stimulus package. Under the ARRA, hospitals will receive incentive ...

... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... of three MedCounselor consumer drug information modules for pharmacies and ... to take medications safely, assists in identifying unknown tablets or ... indispensable in helping to increase consumer compliance to their drug ...

... , KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir ... to issue its second quarter of 2009 earnings results on Thursday, August ... at 11:00 A.M. EDT that morning. , , ... listen live, please go to www.kcsa.com approximately five ...

... Va., Aug. 6 Sunrise Senior Living, Inc. (NYSE: ... second quarter of 2009. Sunrise will host a conference call ... discuss the financial results. , , "Our restructuring ... expense controls. In recent weeks we have seen a modest lift ...

Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference CSC to Help Georgia Hospital Association Members Achieve 'Meaningful Use' of Electronic Health Records Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results Sunrise Reports Financial Results for Second-Quarter 2009

... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...

200 L, Bulk, yellow Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....

... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...

Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...

Medicine Products:

EcoPack D200 200 L Pipette Tip Finntip 250 Wide StrataTips Pipet Tips, Flat (1-200 l)